2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1

Factors Predicting Likelihood of Remaining Positive for Rheumatoid Arthritis-Related Autoantibodies Following Autoantibody Screening
Abstract Number: 1L

The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
Abstract Number: 2

Rheumatoid Arthritis (RA)-Related Autoimmunity and Lumbar Bone Mineral Density in a Multi-Ethnic Community-Dwelling Population
Abstract Number: 2L

Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
Abstract Number: 3

The Presence of Rheumatoid Factor Is Associated with Lower Bone Mass in Korean Health Screening Male Subjects without Clinically Apparent Arthritis
Abstract Number: 3L

Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial
Abstract Number: 4

Rheumatoid Arthritis (RA)-Related Joint Symptoms and Thoracic Bone Mineral Density in an RA-Free Community Dwelling Population
Abstract Number: 4L

Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 5

Rheumatoid Arthritis and Periodontitis: Association and Characteristics of Chronic Periodontitis
Abstract Number: 5L

Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Abstract Number: 6

Lower Omega-3 Fatty Acid Biomarkers Are Associated with Inflammatory Arthritis in a Population Positive for Anti-Citrullinated Protein Antibodies
Abstract Number: 6L

Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Abstract Number: 7

Long-Term Dietary Changes after Rheumatoid Arthritis Diagnosis in Swedish Women: Data from a Population Based Cohort
Abstract Number: 7L

Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Abstract Number: 8

What Factors Relate to Patients Contributing Longitudinal Data Using Smartphone Technology? Findings from RA Patients Participating in Arthritispower Registry

1
2
3
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].